Aileron Therapeutics name Dr Manuel Aivado as new President and CEO

pharmafile | September 14, 2018 | Appointment | |  Aileron, CEO, Massachusetts, Watertown, appointments 

The Watertown Massachusetts-based stapled peptide therapeutics specialist Aileron Therapeutics has appointed former SVP, Chief Medical & Scientific Officer Dr Manuel Aivado as their new President and Chief Executive Officer. Bringing more than 20 years of scientific, medical and executive leadership experience to the role, the established doctor and pharmaceutical executive succeeds Dr John P Longenecker who was appointed interim CEO in May 2015.

“We are very pleased to announce this well-deserved promotion for Dr Aivado,” said Aileron Chairman Jeff Bailey.  “Manuel clearly best exemplifies the skill set and talent needed to lead the company through its next stage of development.”

Dr Aivado, who gained his MD and PhD from the University of Düsseldorf Medical School between 1989-96, began his career in academia, first taking on roles at the University Hospital of Düsseldorf and Harvard Medical School. However after taking on a role as Director, Global Clinical Development Oncology at GlaxoSmithKline in 2006, he made the move into the pharmaceutical industry, an industry which he has worked in ever since.

Dr Aivado commented on his new position: “I am very excited to take on this new responsibility at Aileron as we further expand the clinical development of our lead product candidate, ALRN-6924, into combination therapies.  ALRN-6924 represents the proof-of-concept for Aileron’s stapled peptide technology, which I believe to be capable of producing additional novel drug candidates that address previously undruggable targets,”

“In the future, we plan to broaden the applicability of our technology and expand our external collaborations.  I am pleased with the external recognition that ALRN-6924 and our stapled peptide technology have earned in the scientific community, and I look forward to additional collaborations translating this recognition into therapeutic and commercial success” he continued.

After leaving GSK in 2012 Dr Aivado served as Vice President of Clinical Development and Pharmacovigilance at Taiho Oncology for two and a half years before joining Aileron in 2014.

Related Content


CEO of PixarBio Corporation sentenced to prison for defrauding investors

Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …

Sanofi axes four major players from its executive committee

Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief …


Dr Richard Torbett is named as the new Chief Executive of the ABPI

The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its …

Latest content